Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski has initiated coverage on Teva Pharmaceutical Industries (NYSE: TEVA) with an Outperform rating. The firm has set a price target of $50 for the stock.